GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » EPS (Diluted)

Fusion Pharmaceuticals (Fusion Pharmaceuticals) EPS (Diluted) : $-1.47 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals EPS (Diluted)?

Fusion Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.39. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

Fusion Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was $-0.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

Fusion Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-0.39. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

During the past 3 years, the average EPS without NRIGrowth Rate was 24.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Fusion Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 24.30% per year. The lowest was -115.20% per year. And the median was -41.55% per year.


Fusion Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Fusion Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Pharmaceuticals EPS (Diluted) Chart

Fusion Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -0.76 -3.62 -1.90 -2.00 -1.45

Fusion Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.45 -0.38 -0.25 -0.39

Competitive Comparison of Fusion Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Fusion Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Fusion Pharmaceuticals's PE Ratio falls into.



Fusion Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Fusion Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-94.897-0)/65.612
=-1.45

Fusion Pharmaceuticals's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-28.179-0)/73.176
=-0.39

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusion Pharmaceuticals  (NAS:FUSN) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Fusion Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
Executives
Teresa Marie Bitetti director 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender director 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev officer: Chief Medical Officer C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant director, officer: Chief Executive Officer FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon officer: Chief Scientific Officer C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat officer: President and CBO FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom director 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee director C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley officer: Chief Financial Officer 251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p. 10 percent owner 18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary officer: Chief Medical Officer 830 WINTER STREET, WALTHAM MA 02452